Anti-T-Lymphocyte Globulin (ATG) in Renal Transplantation of Kidneys With a Non-Heart-Beating (NHB) Donor

PHASE3UnknownINTERVENTIONAL
Enrollment

180

Participants

Timeline

Start Date

January 31, 2008

Primary Completion Date

January 31, 2010

Study Completion Date

June 30, 2010

Conditions
Renal Transplant PatientsRecipients of a Kidney From a Non-Heart-Beating Donor
Interventions
DRUG

ATG Fresenius

One gift of ATG Fresenius (9 mg/kg body weight) intravenously during the transplantation procedure. ATG is given in addition to standard immunosuppressive treatment (tacrolimus/MMF/prednisolone)

Trial Locations (1)

6525 GA

RECRUITING

UMC St Radboud Hospital, Nijmegen

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Erasmus Medical Center

OTHER

collaborator

Maastricht University

OTHER

collaborator

Leiden University Medical Center

OTHER

collaborator

UMC Utrecht

OTHER

collaborator

University Medical Center Groningen

OTHER

collaborator

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

OTHER

lead

Radboud University Medical Center

OTHER